The Association between Type-2 Diabetes Duration and Major Adverse Cardiac Events after Percutaneous Coronary Intervention
Background. Diabetes is an independent risk factor for coronary artery disease and portends adverse prognosis in diabetic patients undergoing percutaneous coronary intervention (PCI) compared to nondiabetic patients. Few studies are currently available regarding the relationship between diabetes dur...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2021/7580486 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561296286941184 |
|---|---|
| author | Botey Katamu Benjamin Chunguang Qiu Zhanying Han Wenjie Lu Guoju Sun Xiaofei Qin Xule Wang Xi Wang Ran Li Liang Pan |
| author_facet | Botey Katamu Benjamin Chunguang Qiu Zhanying Han Wenjie Lu Guoju Sun Xiaofei Qin Xule Wang Xi Wang Ran Li Liang Pan |
| author_sort | Botey Katamu Benjamin |
| collection | DOAJ |
| description | Background. Diabetes is an independent risk factor for coronary artery disease and portends adverse prognosis in diabetic patients undergoing percutaneous coronary intervention (PCI) compared to nondiabetic patients. Few studies are currently available regarding the relationship between diabetes duration and major adverse cardiac events (MACEs) post-PCI. This study is aimed at assessing the association between diabetes duration and major adverse cardiac events after PCI. Methods. A total of 302 cases of diabetic patients undergoing an elective PCI with drug-eluting stent (DES) deployment and or percutaneous transluminal coronary angioplasty (PTCA) using a drug-coated balloon (DCB) were prospectively studied. We divided patients into three groups based on diabetes duration: <5 years group (n=165), 5–10 years’ group (n=72), and ≥10 years’ group (n=65). Angiographic and clinical follow-up were conducted 12 months after the procedures for all the patients and at any given time during the study when needed. Results. A significantly higher rate of myocardial infarction (MI) in diabetic patients with the longest diabetes duration (7.7% vs. 0% and 0.6%, P=0.001) was observed compared with groups of shorter duration. Repeat coronary revascularization was found to be significantly higher in the >10-year group than was it in groups with shorter duration of diabetes (23.1% vs. 19.4% and 9.10%, P=0.03). After adjustment for confounding risk factors, longer diabetes duration remained an independent predictor of MI (hazard ratio (HR): 5.525, confidence interval (CI): 1.273-23.978, P=0.022) and repeat revascularization (HR: 1.608, CI: 1.058-2.443, P=0.026). Repeat revascularization was significantly related to the progression of nontreated lesions (De novo lesions 20% vs. 18% and 7.3%, P=0.009) compared to previously treated lesions (target lesion revascularization (TLR) 3% vs. 1.3% and 2%, P=0.774). However, all-cause mortality was not significantly different among the groups (3.1% vs. 5.6% and 0.6%, P=0.06, HR: 2.403, CI: 0.464-12.436, P=0.293). Conclusion. Diabetes duration was associated with significant differences in major adverse cardiac events after the percutaneous coronary intervention; the longest diabetes duration portended higher rates of MACEs than shorter duration at the 12-month follow-up. |
| format | Article |
| id | doaj-art-88dfc6bcc9ea47509b7830ff6413e130 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-88dfc6bcc9ea47509b7830ff6413e1302025-02-03T01:25:27ZengWileyJournal of Diabetes Research2314-67452314-67532021-01-01202110.1155/2021/75804867580486The Association between Type-2 Diabetes Duration and Major Adverse Cardiac Events after Percutaneous Coronary InterventionBotey Katamu Benjamin0Chunguang Qiu1Zhanying Han2Wenjie Lu3Guoju Sun4Xiaofei Qin5Xule Wang6Xi Wang7Ran Li8Liang Pan9The First Affiliated Hospital of Zhengzhou University, ChinaThe First Affiliated Hospital of Zhengzhou University, ChinaThe First Affiliated Hospital of Zhengzhou University, ChinaThe First Affiliated Hospital of Zhengzhou University, ChinaThe First Affiliated Hospital of Zhengzhou University, ChinaThe First Affiliated Hospital of Zhengzhou University, ChinaThe First Affiliated Hospital of Zhengzhou University, ChinaThe First Affiliated Hospital of Zhengzhou University, ChinaThe First Affiliated Hospital of Zhengzhou University, ChinaThe First Affiliated Hospital of Zhengzhou University, ChinaBackground. Diabetes is an independent risk factor for coronary artery disease and portends adverse prognosis in diabetic patients undergoing percutaneous coronary intervention (PCI) compared to nondiabetic patients. Few studies are currently available regarding the relationship between diabetes duration and major adverse cardiac events (MACEs) post-PCI. This study is aimed at assessing the association between diabetes duration and major adverse cardiac events after PCI. Methods. A total of 302 cases of diabetic patients undergoing an elective PCI with drug-eluting stent (DES) deployment and or percutaneous transluminal coronary angioplasty (PTCA) using a drug-coated balloon (DCB) were prospectively studied. We divided patients into three groups based on diabetes duration: <5 years group (n=165), 5–10 years’ group (n=72), and ≥10 years’ group (n=65). Angiographic and clinical follow-up were conducted 12 months after the procedures for all the patients and at any given time during the study when needed. Results. A significantly higher rate of myocardial infarction (MI) in diabetic patients with the longest diabetes duration (7.7% vs. 0% and 0.6%, P=0.001) was observed compared with groups of shorter duration. Repeat coronary revascularization was found to be significantly higher in the >10-year group than was it in groups with shorter duration of diabetes (23.1% vs. 19.4% and 9.10%, P=0.03). After adjustment for confounding risk factors, longer diabetes duration remained an independent predictor of MI (hazard ratio (HR): 5.525, confidence interval (CI): 1.273-23.978, P=0.022) and repeat revascularization (HR: 1.608, CI: 1.058-2.443, P=0.026). Repeat revascularization was significantly related to the progression of nontreated lesions (De novo lesions 20% vs. 18% and 7.3%, P=0.009) compared to previously treated lesions (target lesion revascularization (TLR) 3% vs. 1.3% and 2%, P=0.774). However, all-cause mortality was not significantly different among the groups (3.1% vs. 5.6% and 0.6%, P=0.06, HR: 2.403, CI: 0.464-12.436, P=0.293). Conclusion. Diabetes duration was associated with significant differences in major adverse cardiac events after the percutaneous coronary intervention; the longest diabetes duration portended higher rates of MACEs than shorter duration at the 12-month follow-up.http://dx.doi.org/10.1155/2021/7580486 |
| spellingShingle | Botey Katamu Benjamin Chunguang Qiu Zhanying Han Wenjie Lu Guoju Sun Xiaofei Qin Xule Wang Xi Wang Ran Li Liang Pan The Association between Type-2 Diabetes Duration and Major Adverse Cardiac Events after Percutaneous Coronary Intervention Journal of Diabetes Research |
| title | The Association between Type-2 Diabetes Duration and Major Adverse Cardiac Events after Percutaneous Coronary Intervention |
| title_full | The Association between Type-2 Diabetes Duration and Major Adverse Cardiac Events after Percutaneous Coronary Intervention |
| title_fullStr | The Association between Type-2 Diabetes Duration and Major Adverse Cardiac Events after Percutaneous Coronary Intervention |
| title_full_unstemmed | The Association between Type-2 Diabetes Duration and Major Adverse Cardiac Events after Percutaneous Coronary Intervention |
| title_short | The Association between Type-2 Diabetes Duration and Major Adverse Cardiac Events after Percutaneous Coronary Intervention |
| title_sort | association between type 2 diabetes duration and major adverse cardiac events after percutaneous coronary intervention |
| url | http://dx.doi.org/10.1155/2021/7580486 |
| work_keys_str_mv | AT boteykatamubenjamin theassociationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT chunguangqiu theassociationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT zhanyinghan theassociationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT wenjielu theassociationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT guojusun theassociationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT xiaofeiqin theassociationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT xulewang theassociationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT xiwang theassociationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT ranli theassociationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT liangpan theassociationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT boteykatamubenjamin associationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT chunguangqiu associationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT zhanyinghan associationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT wenjielu associationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT guojusun associationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT xiaofeiqin associationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT xulewang associationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT xiwang associationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT ranli associationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention AT liangpan associationbetweentype2diabetesdurationandmajoradversecardiaceventsafterpercutaneouscoronaryintervention |